Actionable news
All posts from Actionable news
Actionable news in OVAS: Ovascience Inc.,

Geron (GERN) Q1 Earnings: What's in Store for the Stock?

Geron Corporation GERN is scheduled to report first quarter 2016 results on May 5 after the market closes. The company’s fourth quarter 2015 loss was in-line with expectations. Let’s see how things are shaping up for the first quarter announcement.

Focus Remains on Imetelstat

With Geron being a development stage company, investor focus will remain on the company’s pipeline progress. Geron currently has one candidate in its pipeline, imetelstat, which is being developed in collaboration with Johnson & Johnson’s JNJ Janssen Biotech.

Imetelstat is currently in a phase II study (IMbark) in patients with DIPSS intermediate-2 or high-risk myelofibrosis who have relapsed after or are refractory to a JAK inhibitor. An internal review to determine the adequacy of one or both of the initial dosing arms is slated for the second half of the year. Based on this review, a decision will be taken regarding the continuation/halting/modification of the dosing arms or the selection of alternative doses.

Imetelstat is in a phase II/III study as well for myelodysplastic syndrome (MDS). An internal review of this study (to support advancement into Part 2) is also expected in the second half of the year.

On the fourth quarter call, Geron...